BioNTech SE

BNTX

Company Profile

  • Business description

    BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

  • Contact

    An der Goldgrube 12
    MainzRPD-55131
    DEU

    T: +49 613190840

    E: [email protected]

    https://www.biontech.de

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2024

    Employees

    6,133

BioNTech SE News & Analysis

stocks

COVID-19 vaccine booster plans match our expectations

We don’t expect any changes to our fair value estimates or moat ratings for the mRNA manufacturers.
stocks

Waiving vaccine IP doesn't affect market assessment: Morningstar

We are not changing our fair values to COVID-19 vaccine firms following the proposed waiver on intellectual property protection.
stocks

Should you invest in the vaccine makers?

Demand for covid-19 vaccines has seen interest in pharma stocks soar, but Morningstar analysts think this is a temporary trend.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,450.9064.30-0.76%
CAC 407,240.7013.720.19%
DAX 4019,068.7635.120.18%
Dow JONES (US)43,910.98382.15-0.86%
FTSE 1008,035.129.350.12%
HKSE19,823.4523.43-0.12%
NASDAQ19,281.4017.36-0.09%
Nikkei 22538,721.66654.43-1.66%
NZX 50 Index12,674.4974.87-0.59%
S&P 5005,983.9917.36-0.29%
S&P/ASX 2008,193.4062.20-0.75%
SSE Composite Index3,439.2817.310.51%

Market Movers